New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
10:01 EDTCNCE, HAR, LH, DGX, LINTA, HSNI, IBP, TLMR, EGRX, FLXNOn The Fly: Analyst Initiation Summary
Concert Pharmaceuticals (CNCE) initiated with a Buy at UBS and an Outperform at JMP Securities... Eagle Pharmaceuticals (EGRX) initiated with a Buy at Cantor and an Overweight at Piper Jaffray... Talmer Bancorp (TLMR) initiated with an Outperform at Keefe Bruyette, an Overweight at JPMorgan, a Strong Buy at Raymond James and an Outperform at RBC Capital... HSN, Inc. (HSNI) initiated with a Buy at UBS... Installed Building Products (IBP) initiated with a Buy at Deutsche Bank and a Neutral at SunTrust... Liberty Interactive (LINTA) initiated with a Buy at UBS and Craig-Hallum... Flexion (FLXN) initiated with a Buy at Needham... LabCorp (LH) assumed with a Neutral at Piper Jaffray... Quest Diagnostics (DGX) assumed with a Neutral at Piper Jaffray... Harman (HAR) initiated with an Outperform at Raymond James.
News For CNCE;EGRX;TLMR;IBP;HSNI;LINTA;DGX;LH;HAR;FLXN From The Last 14 Days
Check below for free stories on CNCE;EGRX;TLMR;IBP;HSNI;LINTA;DGX;LH;HAR;FLXN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 25, 2014
08:32 EDTDGXQuest Diagnostics price target raised to $74 from $68 at Maxim
Subscribe for More Information
July 24, 2014
07:05 EDTDGXQuest Diagnostics narrows 2014 adjusted EPS view to $4.00-$4.10 from $3.95-$4.15
Subscribe for More Information
07:02 EDTDGXQuest Diagnostics reports Q2 adjusted EPS $1.08, consensus $1.06
Subscribe for More Information
July 23, 2014
07:06 EDTEGRXEagle Pharmaceuticals says FDA approves Ryanodex for treatment of MH
Subscribe for More Information
July 22, 2014
07:08 EDTDGXLife Sciences highlights this week at Canaccord
Canaccord highlighted six diagnostic names that report this week and recommends buying Top Pick IDEXX (IDXX) into the print given strong recurring razor/razorblade sales and consistent organic growth. The analyst expects Hold rated Quest Diagnostics (DGX) to report upside to Street estimates of $1.06/$1.882B, Quidel (QDEL) to have an uneventful report, Exact Sciences (EXAS) to provide an update on numerous catalysts near-term and Abaxis (ABAX) to report earnings below consensus. Lastly, the firm is cautious on Meridian Bioscience (VIVO) following a competitor report last week.
July 21, 2014
08:09 EDTLHLabCorp price target raised to $130 from $120 at Maxim
Subscribe for More Information
July 18, 2014
12:04 EDTLHLabCorp pullback a buying opportunity, says Maxim
Subscribe for More Information
11:25 EDTLHPiper awaits notable volume recovery to get more positive on LabCorp
Piper Jaffray views LabCorp's in-line quarter as positive and said restored TRICARE coverage may provide added upside, but the firm would like to see notable lab volume recovery and a pullback in the shares before becoming more positive on the stock. Piper raised its price target on the stock to $99 from $98 and maintains its Neutral rating on LabCorp.
06:43 EDTLHLabCorp raises FY14 adjusted EPS to $6.50-$6.75 from $6.40-$6.70
Subscribe for More Information
06:43 EDTLHLabCorp: Q2 sales increase due to test volume
Total test volume increased 5.3%, while revenue per requisition decreased 2.0% due to test and payer mix. Reports Q2 operating income $246.7M, operating cash flow $207.4M, free cash flow $159M
06:41 EDTLHLabCorp reports Q2 adjusted EPS $1.84, consensus $1.77
Subscribe for More Information
July 17, 2014
09:34 EDTLHLabCorp upgraded to Outperform from Market Perform at William Blair
Subscribe for More Information
July 16, 2014
07:00 EDTCNCEConcert Pharmaceuticals says FDA lifts partial clinical hold for CTP-354
Concert Pharmaceuticals announced that the FDA has provided notification that the company has completed the necessary preclinical toxicology testing in order to administer repeated doses of CTP-354 in excess of 6 mg per day, lifting its partial clinical hold. As a result, the company intends to initiate dosing of 12 mg per day of CTP-354 in the third quarter of this year as part of its ongoing multiple ascending dose Phase 1 trial. Concert is initially developing CTP-354 for use in patients with spinal cord injury and in patients with multiple sclerosis to address significant unmet medical needs.
July 14, 2014
14:42 EDTHARHarman initiated with a Buy at Tigress Financial
Subscribe for More Information
08:59 EDTLHLabCorp management to meet with Maxim
Field trip to company lab to be held in New Jersey on July 15 hosted by Maxim.
July 13, 2014
15:18 EDTHSNIJ.C. Penney CEO successor search faces setback, WSJ says
It appears that J.C. Penney (JCP) is not having an easy time of identifying a successor for current CEO Myron Ullman, says the Wall Street Journal. According to the WSJ report, Mindy Grossman, CEO of HSN (HSNI), who is considered the lead candidate for Ullman's position, had been in talks with J.C. Penney but could not agree on terms and negotiations broke down moths ago. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use